CorConsult Rx - #Repost from @ambcarerx ・・・ Warfarin review! INR goals for most warfarin indications are 2-3, except unless patient has a mechanical mitral valve replacement, in which the INR goal would
![Chris McAloon on Twitter: "ESC 2012 Guidelines on Target INR for Mechanical Valves (note types of valve & risk factors) #CardioEd #EEGC https://t.co/wpbVk30frW https://t.co/NqUjRIqdVu" / Twitter Chris McAloon on Twitter: "ESC 2012 Guidelines on Target INR for Mechanical Valves (note types of valve & risk factors) #CardioEd #EEGC https://t.co/wpbVk30frW https://t.co/NqUjRIqdVu" / Twitter](https://pbs.twimg.com/media/DA-poORU0AMUX-X.jpg)
Chris McAloon on Twitter: "ESC 2012 Guidelines on Target INR for Mechanical Valves (note types of valve & risk factors) #CardioEd #EEGC https://t.co/wpbVk30frW https://t.co/NqUjRIqdVu" / Twitter
![Alfonso Valle on Twitter: "💡Bioprosthetic SAVR or mitral valve replacement➡️Anticoagulation with VKA to an INR of 2.5 is reasonable for 3-6 months postoperatively (Class 2b) 💡On-X AVR ➡️ INR of 1.5-2.0, starting Alfonso Valle on Twitter: "💡Bioprosthetic SAVR or mitral valve replacement➡️Anticoagulation with VKA to an INR of 2.5 is reasonable for 3-6 months postoperatively (Class 2b) 💡On-X AVR ➡️ INR of 1.5-2.0, starting](https://pbs.twimg.com/media/Epf_4bMXYAApE0c.jpg)
Alfonso Valle on Twitter: "💡Bioprosthetic SAVR or mitral valve replacement➡️Anticoagulation with VKA to an INR of 2.5 is reasonable for 3-6 months postoperatively (Class 2b) 💡On-X AVR ➡️ INR of 1.5-2.0, starting
![Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model | Arteriosclerosis, Thrombosis, and Vascular Biology Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model | Arteriosclerosis, Thrombosis, and Vascular Biology](https://www.ahajournals.org/cms/asset/d82b7871-4be0-4967-90ba-5c1cfd083051/28ga01.jpeg)
Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model | Arteriosclerosis, Thrombosis, and Vascular Biology
![Proposed antithrombotic algorithm after valvular heart procedures. a... | Download Scientific Diagram Proposed antithrombotic algorithm after valvular heart procedures. a... | Download Scientific Diagram](https://www.researchgate.net/publication/324526905/figure/fig1/AS:616004577153027@1523878344456/Proposed-antithrombotic-algorithm-after-valvular-heart-procedures-a-Includes-atrial.png)
Proposed antithrombotic algorithm after valvular heart procedures. a... | Download Scientific Diagram
![Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve - Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve -](https://ars.els-cdn.com/content/image/1-s2.0-S0002870320301940-gr2.jpg)
Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve -
![PDF) LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: Results from the "LOWERING-IT" Trial PDF) LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: Results from the "LOWERING-IT" Trial](https://www.researchgate.net/profile/Ferdinando-Carlo-Sasso/publication/45090126/figure/fig1/AS:667199467446274@1536084157191/figure-fig1_Q320.jpg)
PDF) LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: Results from the "LOWERING-IT" Trial
![U.S. FDA Grants Expanded Labeling Claim to On-X Life Technologies, Reducing Blood-Thinning Requirements for Heart Valve Patients | Business Wire U.S. FDA Grants Expanded Labeling Claim to On-X Life Technologies, Reducing Blood-Thinning Requirements for Heart Valve Patients | Business Wire](https://mms.businesswire.com/media/20150402005154/en/460461/5/On-x_heart_valve_Infographic_highres.jpg)
U.S. FDA Grants Expanded Labeling Claim to On-X Life Technologies, Reducing Blood-Thinning Requirements for Heart Valve Patients | Business Wire
![Edoxaban May Be Effective Treatment for Atrial Fibrillation After Transcatheter Aortic Valve Replacement | Mount Sinai - New York Edoxaban May Be Effective Treatment for Atrial Fibrillation After Transcatheter Aortic Valve Replacement | Mount Sinai - New York](https://www.mountsinai.org/files/MSHealth/Assets/Global/Newsroom/2021/MSHS-Newsroom-StudyDesign-2col-770x420.jpg)
Edoxaban May Be Effective Treatment for Atrial Fibrillation After Transcatheter Aortic Valve Replacement | Mount Sinai - New York
![Comparison of warfarin dosage needed to achieve target INR before and after cardiac surgery - The British Journal of Cardiology Comparison of warfarin dosage needed to achieve target INR before and after cardiac surgery - The British Journal of Cardiology](https://bjcardio.co.uk/wp-content/uploads/2016/01/table-14.png)
Comparison of warfarin dosage needed to achieve target INR before and after cardiac surgery - The British Journal of Cardiology
![Follow-up and management of valvular heart disease patients with prosthetic valve: a clinical practice guideline for Indian scenario | SpringerLink Follow-up and management of valvular heart disease patients with prosthetic valve: a clinical practice guideline for Indian scenario | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12055-019-00789-z/MediaObjects/12055_2019_789_Fig3_HTML.png)
Follow-up and management of valvular heart disease patients with prosthetic valve: a clinical practice guideline for Indian scenario | SpringerLink
![2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation](https://www.ahajournals.org/cms/asset/f9f18a29-b960-44ca-ac4a-288f538d8312/cir.0000000000000923.tab45.gif)
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation
![Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. - Abstract - Europe PMC Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. - Abstract - Europe PMC](https://europepmc.org/articles/PMC3699194/bin/nihms482039f1.jpg)